Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) rose 1.3% on Friday. The company traded as high as $3.91 and last traded at $3.86. Approximately 70,282 shares traded hands during trading, a decline of 92% from the average session volume of 842,200 shares. The stock had previously closed at $3.81.
Ampliphi Biosciences Price Performance
The firm has a 50 day simple moving average of $4.64 and a 200-day simple moving average of $6.86.
Ampliphi Biosciences Company Profile
AmpliPhi Biosciences Corporation was a biotechnology company focused on developing bacteriophage-based therapies for bacterial infections. Bacteriophages are viruses that selectively target and destroy specific bacteria, and the company’s approach was intended to address infections caused by antibiotic-resistant pathogens.
Its development pipeline included AB-SA01, an investigational phage therapy targeting Staphylococcus aureus, and AB-PA01, a therapy designed to target Pseudomonas aeruginosa.
See Also
- Five stocks we like better than Ampliphi Biosciences
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
